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Summary
 
The formation of the pre-B cell receptor (BCR) corresponds to an important checkpoint in B
cell development that selects pro-B (pre-BI) cells expressing a functionally rearranged immu-
noglobulin 
 
m
 
 (Ig
 
m
 
) heavy chain protein to undergo the transition to the pre-B (pre-BII) cell
stage. The pre-BCR contains, in addition to Ig
 
m
 
, the surrogate light chains 
 
l
 
5 and VpreB and
the signal transducing proteins Ig
 
a
 
 and Ig
 
b
 
. The absence of one of these pre-BCR compo-
nents is known to arrest B cell development at the pre-BI cell stage. Disruption of the 
 
Pax5
 
gene, which codes for the B cell–specific activator protein (BSAP), also blocks adult B lym-
phopoiesis at the pre-BI cell stage. Moreover, expression of the 
 
mb-1
 
 (Ig
 
a
 
) gene and V
 
H
 
-to-
D
 
H
 
J
 
H
 
 recombination at the
 
 IgH
 
 locus are reduced in Pax5-deficient B lymphocytes 
 
z
 
10- and
 
z
 
50-fold, respectively. Here we demonstrate that complementation of these deficiencies in
pre-BCR components by expression of functionally rearranged
 
 Ig
 
m
 
 and chimeric 
 
Ig
 
m
 
-Ig
 
b
 
transgenes fails to advance B cell development to the pre-BII cell stage in 
 
Pax5
 
 (
 
2/2
 
) mice in
contrast to 
 
RAG2
 
 (
 
2/2
 
) mice. Furthermore, the pre-BCR is stably expressed on cultured pre-
BI cells from 
 
Ig
 
m
 
 transgenic, Pax5-deficient bone marrow, but is unable to elicit its normal sig-
naling responses. In addition, the early developmental block is unlikely to be caused by the ab-
sence of a survival signal, as it could not be rescued by expression of a 
 
bcl2
 
 transgene in Pax5-
deficient pre-BI cells. Together, these data demonstrate that the absence of Pax5 arrests adult B
lymphopoiesis at an early developmental stage that is unresponsive to pre-BCR signaling.
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A
 
n important checkpoint in B cell development con-
trols the transition from the pro-B (pre-BI) to the pre-B
(pre-BII) cell stage that is initiated upon completion of a
productive rearrangement at the immunoglobulin heavy
chain (
 
IgH
 
) locus. A consequence of expressing the mem-
brane-bound Ig
 
m
 
 protein is the transient formation of the
pre-B cell receptor (BCR).
 
1
 
 Signaling initiated by this re-
ceptor promotes allelic exclusion at the 
 
IgH
 
 locus, stimu-
lates proliferative cell expansion, and induces differentiation
to small pre-BII cells undergoing Ig light chain gene rear-
rangements (for review see reference 1). In addition to the
Ig
 
m
 
 protein, the pre-BCR consists of the two nonpoly-
morphic, surrogate light chains, 
 
l
 
5 and VpreB, as well as
the signal transducing proteins Ig
 
a
 
 and Ig
 
b
 
 whose expres-
sion is initiated early in B lymphopoiesis (for review see
reference 2). B cell development is arrested at the pro-B
(pre-BI) cell stage in mice that lack one component of ei-
ther the pre-BCR (mIg
 
m
 
 [reference 3], 
 
l
 
5 [reference 4],
and Ig
 
b
 
 [reference 5]) or of the V(D)J recombination
machinery [RAG1; reference 6), RAG2 (7), DNA-depen-
dent protein kinase (DNA-PK; reference 8)]. However,
expression of a functionally rearranged 
 
Ig
 
m
 
 transgene is able
to complement the recombination defects of both severe
combined immunodeficiency (
 
scid
 
) and 
 
RAG
 
 mutant mice,
thus resulting in pre-BCR formation and subsequent pro-
gression to the small pre-BII cell stage (9–11). The early
expression of a rearranged 
 
Ig
 
m
 
 transgene significantly short-
ens the duration of pro-B cell development by directly in-
ducing differentiation to small pre-BII cells (12). Likewise,
expression of a functionally rearranged 
 
k
 
 light chain gene is
capable of activating the pre-B cell transition in 
 
l
 
5-defi-
cient mice (13, 14).
 
1
 
Abbreviations used in this paper
 
: APC, allophycocyanin; BCR, B cell re-
ceptor; BSAP, B cell–specific activator protein; DNA-PK, DNA-depen-
dent protein kinase; IgH, immunoglobulin heavy chain; RAG, recombi-
nation activating gene; scid, severe combined immune deficiency; TdT,
terminal deoxynucleotidyl transferase.
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Pax5 Function in Early B Cell Development
 
The Ig
 
a
 
 and Ig
 
b
 
 proteins form a disulfide-linked het-
erodimer that is associated through its transmembrane do-
main with the Ig molecule in the pre-BCR and BCR. This
heterodimer is not only essential for surface transport of Igs,
but also constitutes the signal transducing unit of these re-
ceptors (for review see references 2, 15). The Ig
 
a
 
 and Ig
 
b
 
proteins both initiate signaling via immunoreceptor ty-
rosine-based activation motifs (ITAMs), which become
phosphorylated upon receptor engagement and recruit in-
tracellular effectors such as protein-tyrosine kinases to the
receptor (2, 15). Apart from these motifs, the cytoplasmic
tails of Ig
 
a
 
 and Ig
 
b
 
 differ considerably in sequence, but yet
appear to fulfill redundant functions in B cell development.
Chimeric receptors, consisting of the Ig
 
m
 
 protein fused to
the cytoplasmic domain of either the Ig
 
a
 
 or Ig
 
b
 
 protein,
are each independently sufficient to induce the pre-B cell
transition (16, 17) and to signal B cell maturation (18) in
transgenic mice.
Insight into the transcriptional control of early B cell de-
velopment has recently been gained by gene targeting in the
mouse. One of the critical transcription factors thus implicated
in early B lymphopoiesis is the B cell–specific activator pro-
tein (BSAP), which is encoded by the 
 
Pax5
 
 gene (for review
see references 19, 20). 
 
Pax5
 
 is expressed from the earliest B
lineage–committed precursor cell up to the mature B cell stage
(21–23), and, consistent with this expression pattern, is essen-
tial for B lineage commitment in the fetal liver (24). How-
ever, in adult bone marrow, Pax5 is required later for the
progression of B cell development beyond the early pro-B
(pre-BI) cell stage (24, 25). Interestingly, the V
 
H
 
-to-D
 
H
 
J
 
H
 
recombination at the 
 
IgH
 
 locus is 
 
z
 
50-fold reduced in Pax5-
deficient pre-BI cells (24). Moreover, the 
 
mb-1
 
 (
 
Ig
 
a
 
) gene,
which has been identified as one of five direct BSAP (Pax5)
targets, is expressed at an 
 
z
 
10-fold lower level in these
pre-BI cells, whereas Pax5 is not involved in the control of
 
l
 
5
 
, 
 
VpreB
 
, and 
 
B29
 
 (
 
Ig
 
b
 
) expression (24, 26). Hence, the
synthesis of two pre-BCR components, Ig
 
m
 
 and Ig
 
a
 
, is af-
fected in early B lymphocytes of 
 
Pax5 
 
mutant mice.
Here we have tested the hypothesis that the inability to
express a pre-BCR might be the cause for the B cell devel-
opmental block in the bone marrow of Pax5-deficient
mice. For this purpose, we have introduced functionally
rearranged 
 
Ig
 
m
 
 and chimeric 
 
Ig
 
m
 
–Ig
 
b
 
 transgenes into the
 
Pax5 
 
mutant background. These transgenes were able to
neither advance B cell development to the small pre-BII
cell stage nor to elicit normal signaling responses, although
the pre-BCR was expressed on the 
 
Ig
 
m
 
 transgenic, Pax5-
deficient pre-BI cells. Moreover, expression of a 
 
bcl2
 
 trans-
gene was also incapable of rescuing the early developmental
block which is thus unlikely to result from the absence of a
survival signal in 
 
Pax5
 
 mutant B lymphocytes. These data
therefore demonstrate that Pax5 fulfills an essential function
during pro-B cell development before the pre-BCR stage.
 
Materials and Methods
 
Mice.
 
The different mouse strains were maintained on the
hybrid C56BL/6 
 
3
 
 129/Sv background. The genotype of 
 
Pax5
 
mutant mice (25) was determined by PCR analysis as previously
described (24). 
 
RAG2 
 
mutant mice (7) were genotyped by PCR
amplification with the following oligonucleotides: 5
 
9
 
-GCAACA-
TGTTATCCAGTAGCCGGT-3
 
9
 
 (primer 1), 5
 
9
 
-TTGGGAG-
GACACTCACTTGCCAGT-3
 
9
 
 (primer 2), and 5
 
9
 
-GTATG-
CAGCCGCCGCATTGCATCA-3
 
9
 
 (primer 3). A 605-bp PCR
product was amplified from the wild-type 
 
RAG2
 
 allele with
primer pair 1 and 2 and a 1-kb DNA fragment from the mutant
 
RAG2
 
 allele with the pair 1 and 3. For simplicity, the mouse–
human hybrid transgene 
 
mIg
 
m
 
–Ig
 
b
 
 (YS:VV; references 16, 27) is
referred to as 
 
Ig
 
m
 
–Ig
 
b
 
 in this manuscript and the functionally re-
arranged mouse Ig
 
m
 
 transgene of the line M54 (28) as 
 
Ig
 
m
 
. The
presence of the 
 
Ig
 
m
 
 transgene expressing the membrane form of
the 
 
m heavy chain was detected by Southern blot analysis with
radiolabeled pBR322 DNA as previously described (28). The
Igm–Igb transgene was identified by PCR amplification with the
primers 59-GCCTTTGAGAACCTGTGGGC-39 and 59-CCT-
CATTCCTGGCCTGG-39 (100-bp PCR product). The trans-
genic mouse strain Em-bcl-2-36 (29), which expresses a human
bcl-2 cDNA under the control of the SV40 promoter and IgH Em
enhancer in B and T lymphocytes (30), was genotyped by PCR
using the primers 59-GCAGACACTCTATGCCTGTGTGG-39
and 59-GGAACCTTACTTCTGTGGTGTGA-39 (504-bp PCR
product).
Pre-BI Cell Cultures. Cell suspensions prepared from mouse
bone marrow or fetal liver (at embryonic day 16.5 or 17.5) were
plated at limiting dilutions on a semiconfluent layer of g-irradi-
ated stromal ST2 cells in the presence of IL-7–containing me-
dium as previously described (24). After 1 wk of in vitro culture,
individual pre-BI cell colonies were collected and further propa-
gated as a cell pool. The long-term proliferation potential of these
pre-BI cell pools was analyzed for at least 1 mo.
Antibodies and Flow Cytometry. The following mAbs were
purified from hybridoma supernatants on protein G–sepharose
columns (Pharmacia Biotech AB, Uppsala, Sweden) and conju-
gated with sulfo-NHS-biotin (Pierce Chemical Co., Rockford,
IL) as recommended by the suppliers: anti-c-kit mAb (ACK4;
reference 31), anti-m mAb (M41.42; reference 32), anti-l5 mAb
(LM34; reference 33), and anti-pre-BCR mAb (SL156; reference
33). The following reagents were purchased from PharMingen
(San Diego, CA): biotinylated anti-CD25 mAb (7D4), biotiny-
lated anti-CD43 mAb (S7), biotinylated anti-CD2 mAb (RM2-
5), FITC- and PE-coupled anti-B220/CD45R mAb (RA3-6B2),
FITC-conjugated anti-m mAb (R6-60.2), APC-coupled anti–
c-kit mAb (ACK45), purified anti–human Bcl-2 mAb (Bcl-2/
100), and PE-conjugated streptavidin.
8–11-d-old mice were used for flow cytometric analysis, as
older Pax5 mutant mice suffer from disease and generally die
within 3 wk (25). Cultured pre-BI cells or single-cell suspensions
prepared from the bone marrow of these mice were stained with
different antibody combinations and subsequently analyzed on a
FACScanÒ flow cytometer (Becton Dickinson, San Jose, CA) as
previously described (25).
Intracellular Antibody Staining. The cytoplasmic m heavy chain
protein was detected in bone marrow pre-BI cells as previously
described (34). In brief, bone marrow cells were incubated with
PE-coupled anti-B220 (RA3-6B2) and allophycocyanin (APC)-
conjugated anti–c-kit (ACK45) antibodies at 48C, washed twice
with PBS, and then fixed with 2% paraformaldehyde (Fluka AG,
Buchs, Switzerland) in PBS at room temperature for 20 min, fol-
lowed by two washes with PBS. The fixed cells were subsequently
permeabilized with 0.5% saponin (Sigma Chemical Co., St. Louis,
MO) in 2% FCS/PBS and were simultaneously stained with737 Thévenin et al.
FITC-conjugated anti-m antibody (R6-60.2) for 40 min at 48C,
then washed twice in saponin buffer and once in 2% FCS/PBS be-
fore analysis on a FACSVantageÒ TSO flow cytometer (Becton
Dickinson). Cultured bcl-2 transgenic, Pax5 (2/2) pre-BI cells were
analyzed for expression of the human Bcl-2 protein by cytoplasmic
staining with an anti–human Bcl-2 mAb (Bcl-2/100; detected with a
PE-coupled goat anti–mouse IgG antibody) as described above.
Western Blot Analysis. Whole cell extracts of in vitro cultured
pre-BI cells were prepared by lysis in 0.25 M Tris, pH 7.5, and
0.1% Triton X-100, followed by removal of insoluble material by
centrifugation. Total protein (10 mg) was separated by 10% SDS-
PAGE, electrotransferred to a nitrocellulose membrane, and then
incubated with a rabbit polyclonal anti-Igb antiserum (27) (di-
luted at 1:1,000). Anti-Igb antibodies were detected by enhanced
chemiluminescence using a horseradish peroxidase–conjugated
donkey anti–rabbit secondary antibody (ECL; Amersham Inter-
national, Arlington Heights, IL).
RNase Protection Analysis. A mouse terminal deoxynucleotidyl
transferase (TdT) riboprobe was generated by inserting a 244-bp
cDNA fragment of the mouse TdT mRNA (35) into the HindIII
and EcoRI sites of pSP64. This cDNA fragment was amplified
from RNA of 70Z/3 cells by reverse transcriptase PCR using the
following primers: 59-GCGGAATTCAAGGTGGATGCTCTC-
GACCAT-39 and 59-GCGAAGCTTCGTGGTTGTCCAGCAT-
CATCT-39. Total RNA was prepared from cultured pre-BI cells
and analyzed by RNase protection assay exactly as previously de-
scribed (24).
Results
Pax5 (BSAP) Is Essential for Early B Cell Development be-
fore the Pre-BCR Stage. Based on the expression of cell
surface markers, we have recently demonstrated that B cell
development is arrested in the bone marrow of Pax5 mu-
tant mice (24) at a similar pro-B (pre-BI) cell stage as in
mice that are deficient in one of the components of the
pre-BCR (mMT [reference 36], l5 [reference 36], and Igb
[reference 5]) or the V(D)J rearrangement machinery (RAG1
[reference 9] and RAG2 [reference 7]). Moreover, Pax5-
deficient pre-BI cells are essentially unable to synthesize the
Igm protein, an important constituent of the pre-BCR, due
to an z50-fold reduction of the VH-to-DHJH recombina-
tion frequency at the IgH locus (24). The inability to form
a functional pre-BCR could therefore explain the early B
cell developmental block observed in Pax5 mutant mice.
This hypothesis makes the clear prediction that expression
of a functionally rearranged Igm transgene in Pax5 mutant
mice should result in the formation of the pre-BCR, thus
traversing this important checkpoint and advancing B cell
development to the pre-BII cell stage. To test this hypoth-
esis, we have introduced a rearranged murine Igm trans-
gene, which directs expression of a membrane-bound Igm
protein under the control of a VH gene promoter (28) into
Pax5 (2/2) mice. As the chosen Igm transgene has not yet
been used for similar experiments, we have also tested its
ability to guide B cell development to the pre-BII cell stage
in RAG2-deficient mice. The transition from the pre-BI to
the pre-BII cell stage is known to be accompanied by the
downregulation of the early markers CD43 and c-kit, by
the initiation of CD2 and CD25 expression, and by an in-
crease in the total B cell number (9, 10, 37). B lymphocytes
from RAG2 (2/2) bone marrow lacking or containing the
Igm transgene were compared by flow cytometric analysis
(Fig. 1), demonstrating that the synthesis of CD43 and c-kit
was indeed downregulated, the expression of CD2 and
CD25 was initiated, and the number of B2201 cells was in-
creased by about twofold in the presence of the transgene.
In marked contrast, the B lymphocyte number and cell sur-
face phenotype did not change in the bone marrow of
Pax5 (2/2) mice irrespective of the presence or absence of
the Igm transgene (Fig. 1). Hence, the Pax5 and RAG2
gene mutations clearly differ, as the presence of a rear-
ranged  Igm transgene is unable to rescue the early B cell de-
velopmental block in Pax5-deficient mice in contrast to
RAG2-deficient mice.
Possible trivial explanations for the failure of the Igm
transgene to induce the pre-B cell transition could be that
Pax5 itself is involved in the transcriptional control of the
transgene or that B cell development is arrested before the
initiation of transgene expression in Pax5 mutant mice. To
investigate these possibilities, we have analyzed the pres-
ence of cytoplasmic Igm protein in c-kit1 B2201 pre-BI
cells of Pax5-deficient bone marrow (Fig. 2 A). No cyto-
plasmic Igm protein could be detected by intracellular
staining in Pax5 (2/2) pre-BI cells in agreement with the
fact that the VH-to-DHJH recombination is drastically re-
duced in these cells (24). In contrast, the Igm protein was
expressed in the majority of Pax5 (2/2) pre-BI cells carry-
ing the transgene. We therefore conclude that early expres-
sion of a rearranged Igm transgene is not sufficient to trigger
the pre-B cell transition in Pax5 mutant mice.
The mb-1 gene coding for Iga was recently shown to be
a direct BSAP (Pax5) target whose expression is reduced
z10-fold in Pax5-deficient pre-BI cells compared with
wild-type cells (26). In addition to the Igm protein, Iga is
therefore a second component of the pre-BCR that is ex-
pressed under the control of Pax5. As the heterodimer con-
sisting of the proteins Iga and Igb constitutes the signal
transducing unit of the pre-BCR (2), it is conceivable that
the reduced Iga expression in Pax5-deficient pre-BI cells
prevents the formation of a functional pre-BCR even in
the presence of a rearranged Igm transgene. To address this
question, we have introduced a chimeric Igm–Igb transgene
(16) into the Pax5 (2/2) background. The Igm component
of this transgene codes for a membrane-bound Ig with two
transmembrane mutations (Y587V, S588V) which prevent
its normal association with the Iga–Igb dimer (27). The
cytoplasmic domain of the fusion protein is encoded by Igb
and directly mediates signaling independent of the presence
of endogenous Iga or Igb proteins (27). Furthermore, the
chimeric Igm–Igb receptor was shown to efficiently acti-
vate transition to the pre-BII cell stage and to induce allelic
exclusion at the IgH locus in RAG-deficient mice (16).
Hence, signaling of this chimeric receptor should be inde-
pendent of the reduced expression levels of both Iga and
Igm proteins that are observed in Pax5-deficient mice.
Nevertheless, the chimeric Igm–Igb gene was unable to ad-
vance B cell development in the bone marrow of Pax5738 Pax5 Function in Early B Cell Development
mutant mice, since its presence neither altered the expression
of cell surface markers nor increased the number of B2201
cells (Fig. 3 A). However, the Igm–Igb fusion protein was
expressed in pre-BI cells regardless of the Pax5 genotype
(Fig. 3 B). Together, these in vivo data indicate that expres-
sion of the pre-BCR is not sufficient to rescue the early B
cell developmental block in Pax5-deficient mice. Hence, the
Pax5 mutation appears to arrest B lymphopoiesis at an early
stage that is not responsive to pre-BCR signaling.
The survival of B cell precursors is controlled by differ-
ential expression of the antiapoptotic genes bcl-2 and bcl-xL
during B lymphopoiesis (38, 39). Interestingly, the bcl-xL
but not the bcl-2 gene is consistently expressed at a 10-fold
lower level in Pax5-deficient pre-BI cells compared with
wild-type cells, although this downregulation was shown
to be an indirect consequence of the absence of Pax5 (26).
In agreement with this finding, the pre-BI cells of Pax5
mutant bone marrow proved to be ultrasensitive to growth
factor withdrawal, as they rapidly undergo apoptosis ex
vivo in the absence of survival signals emanating from the
IL-7 receptor (data not shown). In this context it is inter-
esting to note that the expression of a bcl-2 transgene was
previously shown to promote B cell development in scid
mice (40) that also exhibit a defect in V(D)J recombination
of Ig genes (for review see reference 41). Hence, we inves-
tigated the possibility that sustained cell survival may also
rescue the early developmental block in Pax5-deficient
bone marrow. For this purpose, the same Em-bcl-2-36
transgenic mouse, carrying a human bcl-2 cDNA under the
control of the IgH E m  enhancer (29), was crossed with
Pax5 mutant mice. Expression of the bcl-2 transgene in
Pax5 (2/2) pre-BI cells was demonstrated by cytoplasmic
staining with an anti–human Bcl-2 antibody as well as by
its ability to completely block apoptosis upon IL-7 with-
drawal (data not shown). Nevertheless, the bcl-2 transgene
was unable to advance B cell development to the pre-BII
cell stage, as no CD432 B2201 B lymphocytes were ob-
served in the bone marrow of bcl-2 transgenic, Pax5 (2/2)
Figure 1. Expression of a rearranged Igm transgene fails to advance B cell development in Pax5 mutant mice. Bone marrow cells from 8–11-d-old mice
of the indicated genotype were analyzed by flow cytometry using an FITC-conjugated anti-B220 antibody (RA3-6B2) in combination with biotinylated
anti-CD25 (7D4), anti-CD43 (S7), anti-CD2 (RM2-5), or anti–c-kit (ACK4) antibodies. The biotin-conjugated antibodies were revealed by incubation
with PE-coupled streptavidin. The percentage of B2201 cells is indicated in each quadrant. The number of B2201 cells was consistently lower in the
bone marrow of Pax5 mutant mice compared with RAG2 mutant mice, which may reflect the poorer health of Pax5-deficient mice (25), the ultrasensi-
tivity of Pax5 (2/2) pre-BI cells to apoptotic signals (Nutt, S.L., data not shown), or blockage at different stages of pro-B cell development in the two
mutant mice (see Discussion).739 Thévenin et al.
mice (Fig. 2 B). Instead, deregulated bcl-2 expression led to
a modest increase in CD431 B2201 pre-BI cells similar to
the situation observed in RAG2 mutant mice carrying a bcl-2
transgene (42). Therefore, these data demonstrate that
blocking apoptosis is not sufficient to promote B cell devel-
opment in Pax5 mutant mice.
Stable Expression of the Pre-BCR and Absence of its Normal
Signaling Response in Igm Transgenic, Pax5-deficient Pre-BI
Cells. Expression of a functionally rearranged Igm chain
has previously been shown to alter the IL-7 responsiveness
of precursor B cells in wild-type and RAG2 mutant mice
(10). The proliferative response to IL-7 was considerably
decreased in bone marrow cells of Igm transgenic mice,
thus preventing the establishment of long-term pre-BI cell
cultures (10). One possible reason for this phenomenon
may be the downregulation of c-kit expression in response
to pre-BCR activation (33, 37), which eliminates an essen-
tial costimulatory signal for IL-7–dependent proliferation
of B lymphoid precursor cells (43). To further study the
function of the pre-BCR, we have established pre-BI cell
cultures from bone marrow of Pax5-deficient mice carry-
ing an Igm(-Igb) transgene. These pre-BI cells were cul-
tured in the presence of stromal ST2 cells and IL-7, and
their long-term proliferation potential was assessed after 1 mo
of in vitro culture. Surprisingly, Pax5-deficient pre-BI cells
could be efficiently established and maintained even in the
presence of transgenic Igm or chimeric Igm–Igb proteins
(Table 1). In contrast, no pre-BI cell cultures with long-
term proliferation capacity were obtained from homozy-
gous or heterozygous RAG2 mutant mice carrying an Igm
transgene, as previously described (10). Thus, these data in-
dicate that expression of the Igm protein does not interfere
with the proliferation potential of Pax5-deficient pre-BI
cells in contrast to control B lymphocytes.
Given the possibility to grow Igm transgenic, Pax5 (2/2)
precursor cells, we next investigated whether these cells
could assemble the pre-BCR on their surface. As shown by
flow cytometric analysis, Pax5-deficient pre-BI cells con-
taining or lacking the Igm transgene expressed a similar
level of the surrogate light chain l5 on their surface (Fig. 4
A). In contrast, the Igm protein was only found on the trans-
genic pre-BI cells. Furthermore, staining with a monoclonal
antibody (SL156), which recognizes a conformational epitope
present on the surrogate light chain-Igm complex of the pre-
BCR (33), demonstrated that the Igm protein was part of the
pre-BCR (Fig. 4 A). Three conclusions can be drawn from
these data. First, the pre-BCR is stably expressed on the sur-
face of Igm transgenic, Pax5 (2/2) pre-BI cells despite the
fact that the pre-BCR is only transiently expressed and rap-
idly internalized on wild-type precursor B cells (33, 44,
45). Second, the surrogate light chains are expressed at nor-
mal levels on transgenic, Pax5 (2/2) pre-BI cells, although
their expression is usually downregulated in response to
pre-BCR signaling (9, 10, 37, 38, 44). Third, the Iga pro-
tein is known to be essential for cell surface transport of Igs
(46, 47), and yet the 10-fold lower mb-1 expression in
Pax5-deficient pre-BI cells (26) seems to provide sufficient
Iga protein for pre-BCR formation.
Figure 2. Igm and bcl-2 transgene expression in pre-BI cells of Pax5-
deficient bone marrow. (A) Intracellular Igm staining. Bone marrow cells
of Pax5 mutant mice containing or lacking the Igm transgene were ana-
lyzed by intracellular staining for expression of the Igm protein (see Mate-
rials and Methods). Pre-BI cell were identified by staining with APC-
coupled anti–c-kit (ACK45) and PE-conjugated anti-B220 (RA3-6B2)
antibodies. The presence of the intracellular Igm protein within the c-kit1
B2201 cell population was detected with an FITC-conjugated anti-m an-
tibody (R6-60.2) and is displayed to the right. (B) Expression of a bcl-2
transgene fails to rescue the early B cell developmental block in Pax5-defi-
cient mice. The transgene of the Em-bcl-2-36 strain (29, 30) was crossed
into the Pax5 mutant background, and the bone marrow of 10–14-d-old
Pax5 (2/2) mice was analyzed by flow cytometry using FITC-conju-
gated anti-B220 (RA3-6B2) and biotinylated anti-CD43 (S7) antibodies
(revealed by PE-streptavidin). The percentage of B2201 cells is indicated
in each quadrant. 10 mice of each genotype were analyzed, indicating that
the CD431 B2201 cell population corresponded on average to 5.4%
[Pax5 (2/2)], 7.1% [Pax5 (2/2), bcl-2 transgene], 7.2% [Pax5 (1/1)],
and 10.8% [Pax5 (1/1), bcl-2 transgene] of the total bone marrow cells
(data not shown).740 Pax5 Function in Early B Cell Development
The expression of the TdT gene is rapidly downregu-
lated during the pre-B cell transition in response to expres-
sion of a functionally rearranged Igm protein (37, 38, 48).
The TdT gene is therefore considered to be a downstream
target in the signaling cascade initiated by the pre-BCR
(48). As shown by RNase protection analysis, the level of
TdT transcripts was similar in Pax5-deficient pre-BI cells
regardless of the presence of the Igm transgene (Fig. 4 B,
lanes 2 and 3). In summary, the different results obtained
with cultured pre-BI cells all demonstrate that the pre-
BCR is unable to elicit its normal signaling response in the
absence of Pax5 function.
Discussion
The transcription factor Pax5 (BSAP) is involved in the
control of VH-to-DHJH recombination and in the transcrip-
tional regulation of the mb-1 gene, which results in reduced
expression of the two pre-BCR components, Igm and Iga,
in Pax5-deficient pre-BI cells (24, 26). Here we have dem-
onstrated that complementation of these deficiencies by the
expression of Igm and Igm–Igb transgenes is not sufficient to
initiate the pre-B cell transition in Pax5 mutant mice.
Hence, the inability to form a pre-BCR cannot be the
cause of the early B cell developmental block in mice lack-
ing Pax5. Instead, the absence of Pax5 arrests B cell devel-
Figure 3. Expression of the Igm-Igb transgene is not sufficient to rescue the early developmental arrest in Pax5 mutant mice. (A) Flow cytometric anal-
ysis. Bone marrow cells of Pax5 mutant mice containing or lacking the Igm-Igb transgene (16) were analyzed by flow cytometry as described in the legend
to Fig. 1. (B) Expression of the Igm–Igb fusion protein. Bone marrow pre-BI cells from mice of the indicated genotypes were enriched by short-term
culturing in IL-7 containing medium and then analyzed for Igm–Igb protein expression by immunoblotting (see Materials and Methods). The faster mi-
grating polypeptide corresponds in size to the unglycosylated form of the Igm-Igb fusion protein. The size of marker proteins (given in kD) is indicated
to the left.
Table 1. Long-term Proliferation of Pax5-deficient Pre-BI Cells 
Despite the Expression of Igm Transgenes
Genotype Transgene
Long-term pre-BI cell
growth/mouse
Pax5 (2/2) – 4/4
Pax5 (2/2)I g m 6/6
Pax5 (2/2)I g m -Igb 7/7
RAG2 (2/2) – 9/9
RAG2 (2/2)I g m 0/7
RAG2 (1/2) – 7/7
RAG2 (1/2)I g m 0/8
Bone marrow cells of Pax5 (2/2) mice or fetal liver cells of RAG2
mutant embryos were plated under limiting dilution conditions in the
presence of IL-7 and stromal ST2 cells. Pre-BI cell colonies were subse-
quently pooled, and their long-term proliferation potential was assessed
after 1 mo of in vitro culture. Bone marrow instead of fetal liver had to
be used as a source of B lymphoid progenitors for culturing Pax5-defi-
cient pre-BI cells, as Pax5 is required for B lineage commitment in the
fetal liver (24).741 Thévenin et al.
opment by a different mechanism compared with mice
which lack a component of the pre-BCR (mIgm [reference
3], l5 [reference 4], or Igb [reference 5]) or of the V(D)J
recombination machinery (RAG1 [reference 6], RAG2
[reference 7], or DNA-PK [reference 8]). Consistent with
this conclusion, the lack of Pax5 or RAG2 function has
opposite effects on the in vitro differentiation potential of B
lymphocytes. Pre-BI cells of RAG2 mutant mice efficiently
differentiate ex vivo to the mature B cell stage upon stimu-
lation with IL-4 and anti-CD40 antibodies, which by-
passes in vitro the requirement of Ig gene rearrangements
for further development (49). In contrast, Pax5 mutant
pre-BI cells entirely fail to differentiate under the same in
vitro conditions, further demonstrating a strict dependency
of early B lymphopoiesis on Pax5 (Nutt, S.L., unpublished
data).
It has been notoriously difficult to demonstrate expres-
sion of the pre-BCR on the surface of precursor B cells
(33, 44), which reflects both a slow, inefficient cell surface
transport and rapid, tyrosine phosphorylation–dependent
internalization of this receptor (2, 45). Quite in contrast,
we have now observed stable expression of the pre-BCR
on the surface of Igm transgenic, Pax5-deficient pre-BI
cells. Interestingly, the constitutive cell surface expression
of the pre-BCR correlates with the absence of normal sig-
naling responses. The transgenic, Pax5-deficient pre-BI
cells neither lost their long-term proliferation potential in
the presence of IL-7 and stromal cells nor did they down-
regulate expression of the TdT or surrogate light chain
genes, which are normal responses to pre-BCR signaling in
wild-type precursor B cells (9, 10, 37, 38, 44, 48). There-
fore, it is conceivable that Pax5 may either regulate the ex-
pression of an essential component of the signal transduc-
tion cascade or act in the nucleus as the critical mediator of
pre-BCR signaling. Stimulation of the BCR is known to
result in the phosphorylation and association of the Iga–
Igb heterodimer with the protein-tyrosine kinases Lyn,
Fyn, Blk, Btk, and Syk (50–53). Moreover, the Syk kinase
has been shown to play an important role in pre-BCR sig-
naling (54, 55). However, none of these tyrosine kinase
genes is expressed under the control of Pax5, as shown by a
comprehensive analysis of putative BSAP (Pax5) target
genes (26). Hence, there is at present no evidence that
Pax5 is involved in the expression of cytoplasmic signal
transducers. Moreover, an exclusive role of Pax5 in medi-
ating signal transduction of the pre-BCR seems unlikely
for several reasons. First, Pax5 expression is already initiated
Figure 4. The Pax5 function is required for normal signaling responses
of the pre-BCR. (A) Constitutive expression of the pre-BCR on Pax5-
deficient pre-BI cells carrying the Igm transgene. Pre-BI cells from Pax5
mutant mice were grown for 3 wk on stromal ST2 cells in the presence of
IL-7 followed by flow cytometric analysis with biotinylated anti-l5
(LM34), anti-m (M41.42), and anti–pre-BCR (SL156) antibodies. Incu-
bation with PE-coupled streptavidin was used to visualize the biotinylated
antibodies. Unstained control cells are indicated by a line. Note that the
cell surface expression of l5 in the absence of Igm is in agreement with
the finding that the surrogate light chains l5 and VpreB are expressed in
association with an unidentified 130 kD glycoprotein on the surface of
pre-BI cells before any productive V(D)J rearrangement (44). (B) Expres-
sion of the TdT gene in transgenic, Pax5-deficient pre-BI cells. Total
RNA (10 mg) isolated from cultured pre-BI cells was simultaneously ana-
lyzed for TdT and GAPDH (glyceraldehyde-3-phosphate dehydrogenase)
expression by RNase protection assay. Only the relevant parts of the
autoradiograph containing the RNase-protected fragments are shown.
Pre-BI cells derived from Pax5 (2/2) bone marrow lacking (lane 2) or
containing the Igm transgene (lane 3) were compared with pre-BI cells
established from the fetal liver of a control embryo (lane 1). Note that the
TdT gene is not expressed in fetal B lymphopoiesis (38).742 Pax5 Function in Early B Cell Development
at B lineage commitment long before the pre-BCR stage
and thereafter is maintained at a rather constant level
throughout B lymphopoiesis (21–23). Second, all our at-
tempts have so far failed to demonstrate any alteration in
the posttranslational modification pattern of BSAP (Pax5)
in response to signal transduction (M. Busslinger, unpub-
lished data). Third, the developmental arrest in Pax5 mu-
tant mice is tight (25) rather than leaky as it would be ex-
pected, in analogy to the syk (2/2) mouse (54, 55), for a
mutation in a downstream component of the signal trans-
duction pathway. Last but not least, a role for Pax5 in the
regulation of l5, VpreB, or TdT has recently been excluded
(26), although the expression of these genes is downregu-
lated in response to pre-BCR signaling.
The mouse scid mutation affects the XRCC7 gene cod-
ing for the catalytic subunit of the DNA-PK, which is es-
sential for V(D)J recombination and double-stranded DNA
break repair (8, 41). The phenotype of the scid mouse is
known to be leaky in contrast to the RAG mutations, as
scid B lymphocytes are still able to generate DH-to-JH and
VH-to-DHJH rearrangements at a very low frequency (41).
Hence, the scid and Pax5 mutations appear to be compara-
ble with regard to their low efficiency of Ig gene rearrange-
ments and early B cell developmental block. However, ex-
pression of a bcl-2 transgene in scid mice results in the
accumulation of almost normal numbers of B lymphocytes
that express many markers of mature B cells (40, 56). Due
to the increased life span, the early progenitor cells present
in the bcl-2 transgenic scid bone marrow seem to have a
higher probability to generate productive DH-to-JH rear-
rangements in reading frame 2 and thus to express the trun-
cated Dm protein that promotes maturation to later B cell
stages (56). Interestingly, we have previously shown that
DH-to-JH rearrangements occur relatively frequently in
reading frame 2 in pre-BI cells of Pax5 mutant bone mar-
row (24). Nevertheless, expression of the same bcl-2 trans-
gene fails to promote B cell development in Pax5-deficient
mice, thus further demonstrating that the early arrest of B
lymphopoiesis is neither caused by a rearrangement defect
nor by the lack of a survival signal.
The inability of Igm and bcl-2 transgenes to advance B
cell development and the constitutive cell surface expres-
sion of the pre-BCR strongly argue that B lymphopoiesis is
arrested in Pax5 mutant mice at an early stage that is not
responsive to pre-BCR signaling in the absence of Pax5
function. Consistent with this notion, the cell surface
marker BP-1, which is specifically expressed on late pro-B
(pre-BI) cells (57), is absent on bone marrow cells of Pax5-
deficient mice (24). Therefore, it appears that Pax5 controls
a critical step between initial B lineage commitment and
the pre-BCR stage of adult B lymphopoiesis. In this con-
text it is interesting to note that the interruption of Ras sig-
naling also arrests early B cell development well before the
pre-BCR stage (58). Our analysis of Pax5-deficient pre-BI
cells has recently demonstrated a pleiotropic role of the
transcription factor BSAP (Pax5) in gene regulation during
early B lymphopoiesis (26). Hence, it will be a challenge
for the future to identify the critical, and thus far unknown,
BSAP target gene(s) that mediates the Pax5-dependent
control of early B cell development.
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